Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 308740
  • calendar_today Published On: Jun, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Phosphodiesterase Type 5 (PDE5) Inhibitor market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Phosphodiesterase Type 5 (PDE5) Inhibitor market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital accounting for % of the Phosphodiesterase Type 5 (PDE5) Inhibitor global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Sildenafil segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Phosphodiesterase Type 5 (PDE5) Inhibitor include Eli Lilly, Pfizer, Bayer, Novartis AG, and Merck, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Phosphodiesterase Type 5 (PDE5) Inhibitor market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

Sildenafil

Tadalafil

Avanafil

Vardenafil

Market segment by Application, can be divided into

Hospital

Retail Pharmacy

Online Pharmacies

Other

Market segment by players, this report covers

Eli Lilly

Pfizer

Bayer

Novartis AG

Merck

GlaxoSmithKline plc

Roche

AstraZeneca

BaiYunShan General Factory

SK Chemicals

Teva Pharma

Dong-A ST

Metuchen Pharma

Seoul Pharma

Vectura Group

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Phosphodiesterase Type 5 (PDE5) Inhibitor product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Phosphodiesterase Type 5 (PDE5) Inhibitor, with revenue, gross margin and global market share of Phosphodiesterase Type 5 (PDE5) Inhibitor from 2019 to 2022.

Chapter 3, the Phosphodiesterase Type 5 (PDE5) Inhibitor competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Phosphodiesterase Type 5 (PDE5) Inhibitor market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Phosphodiesterase Type 5 (PDE5) Inhibitor research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Phosphodiesterase Type 5 (PDE5) Inhibitor

1.2 Classification of Phosphodiesterase Type 5 (PDE5) Inhibitor by Type

1.2.1 Overview: Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Type in 2021

1.2.3 Sildenafil

1.2.4 Tadalafil

1.2.5 Avanafil

1.2.6 Vardenafil

1.3 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market by Application

1.3.1 Overview: Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospital

1.3.3 Retail Pharmacy

1.3.4 Online Pharmacies

1.3.5 Other

1.4 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size & Forecast

1.5 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast by Region

1.5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region, (2017-2022)

1.5.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Prospect (2017-2028)

1.5.4 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Prospect (2017-2028)

1.5.6 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Drivers

1.6.2 Phosphodiesterase Type 5 (PDE5) Inhibitor Market Restraints

1.6.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Trends Analysis

2 Company Profiles

2.1 Eli Lilly

2.1.1 Eli Lilly Details

2.1.2 Eli Lilly Major Business

2.1.3 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.1.4 Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Eli Lilly Recent Developments and Future Plans

2.2 Pfizer

2.2.1 Pfizer Details

2.2.2 Pfizer Major Business

2.2.3 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.2.4 Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Pfizer Recent Developments and Future Plans

2.3 Bayer

2.3.1 Bayer Details

2.3.2 Bayer Major Business

2.3.3 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.3.4 Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Bayer Recent Developments and Future Plans

2.4 Novartis AG

2.4.1 Novartis AG Details

2.4.2 Novartis AG Major Business

2.4.3 Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.4.4 Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Novartis AG Recent Developments and Future Plans

2.5 Merck

2.5.1 Merck Details

2.5.2 Merck Major Business

2.5.3 Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.5.4 Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Merck Recent Developments and Future Plans

2.6 GlaxoSmithKline plc

2.6.1 GlaxoSmithKline plc Details

2.6.2 GlaxoSmithKline plc Major Business

2.6.3 GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.6.4 GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 GlaxoSmithKline plc Recent Developments and Future Plans

2.7 Roche

2.7.1 Roche Details

2.7.2 Roche Major Business

2.7.3 Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.7.4 Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 Roche Recent Developments and Future Plans

2.8 AstraZeneca

2.8.1 AstraZeneca Details

2.8.2 AstraZeneca Major Business

2.8.3 AstraZeneca Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.8.4 AstraZeneca Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 AstraZeneca Recent Developments and Future Plans

2.9 BaiYunShan General Factory

2.9.1 BaiYunShan General Factory Details

2.9.2 BaiYunShan General Factory Major Business

2.9.3 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.9.4 BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 BaiYunShan General Factory Recent Developments and Future Plans

2.10 SK Chemicals

2.10.1 SK Chemicals Details

2.10.2 SK Chemicals Major Business

2.10.3 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.10.4 SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 SK Chemicals Recent Developments and Future Plans

2.11 Teva Pharma

2.11.1 Teva Pharma Details

2.11.2 Teva Pharma Major Business

2.11.3 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.11.4 Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Teva Pharma Recent Developments and Future Plans

2.12 Dong-A ST

2.12.1 Dong-A ST Details

2.12.2 Dong-A ST Major Business

2.12.3 Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.12.4 Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Dong-A ST Recent Developments and Future Plans

2.13 Metuchen Pharma

2.13.1 Metuchen Pharma Details

2.13.2 Metuchen Pharma Major Business

2.13.3 Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.13.4 Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Metuchen Pharma Recent Developments and Future Plans

2.14 Seoul Pharma

2.14.1 Seoul Pharma Details

2.14.2 Seoul Pharma Major Business

2.14.3 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.14.4 Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Seoul Pharma Recent Developments and Future Plans

2.15 Vectura Group

2.15.1 Vectura Group Details

2.15.2 Vectura Group Major Business

2.15.3 Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

2.15.4 Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.15.5 Vectura Group Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Phosphodiesterase Type 5 (PDE5) Inhibitor Players Market Share in 2021

3.2.2 Top 10 Phosphodiesterase Type 5 (PDE5) Inhibitor Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Phosphodiesterase Type 5 (PDE5) Inhibitor Players Head Office, Products and Services Provided

3.4 Phosphodiesterase Type 5 (PDE5) Inhibitor Mergers & Acquisitions

3.5 Phosphodiesterase Type 5 (PDE5) Inhibitor New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Market Share by Type (2017-2022)

4.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Application (2017-2022)

5.2 Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2017-2028)

6.2 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2017-2028)

6.3 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country

6.3.1 North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Country (2017-2028)

6.3.2 United States Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

6.3.3 Canada Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

6.3.4 Mexico Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2017-2028)

7.2 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2017-2028)

7.3 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country

7.3.1 Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Country (2017-2028)

7.3.2 Germany Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

7.3.3 France Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

7.3.5 Russia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

7.3.6 Italy Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2017-2028)

8.2 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2017-2028)

8.3 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Region

8.3.1 Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Region (2017-2028)

8.3.2 China Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

8.3.3 Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

8.3.4 South Korea Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

8.3.5 India Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

8.3.7 Australia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2017-2028)

9.2 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2017-2028)

9.3 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country

9.3.1 South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Country (2017-2028)

9.3.2 Brazil Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

9.3.3 Argentina Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2017-2028)

10.2 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2017-2028)

10.3 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size by Country

10.3.1 Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Country (2017-2028)

10.3.2 Turkey Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

10.3.4 UAE Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million) by Region (2017-2022)

Table 5. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Region (2023-2028)

Table 6. Eli Lilly Corporate Information, Head Office, and Major Competitors

Table 7. Eli Lilly Major Business

Table 8. Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 9. Eli Lilly Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Pfizer Corporate Information, Head Office, and Major Competitors

Table 11. Pfizer Major Business

Table 12. Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 13. Pfizer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Bayer Corporate Information, Head Office, and Major Competitors

Table 15. Bayer Major Business

Table 16. Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 17. Bayer Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Novartis AG Corporate Information, Head Office, and Major Competitors

Table 19. Novartis AG Major Business

Table 20. Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 21. Novartis AG Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Merck Corporate Information, Head Office, and Major Competitors

Table 23. Merck Major Business

Table 24. Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 25. Merck Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. GlaxoSmithKline plc Corporate Information, Head Office, and Major Competitors

Table 27. GlaxoSmithKline plc Major Business

Table 28. GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 29. GlaxoSmithKline plc Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. Roche Corporate Information, Head Office, and Major Competitors

Table 31. Roche Major Business

Table 32. Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 33. Roche Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. AstraZeneca Corporate Information, Head Office, and Major Competitors

Table 35. AstraZeneca Major Business

Table 36. AstraZeneca Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 37. AstraZeneca Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. BaiYunShan General Factory Corporate Information, Head Office, and Major Competitors

Table 39. BaiYunShan General Factory Major Business

Table 40. BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 41. BaiYunShan General Factory Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. SK Chemicals Corporate Information, Head Office, and Major Competitors

Table 43. SK Chemicals Major Business

Table 44. SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 45. SK Chemicals Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Teva Pharma Corporate Information, Head Office, and Major Competitors

Table 47. Teva Pharma Major Business

Table 48. Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 49. Teva Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Dong-A ST Corporate Information, Head Office, and Major Competitors

Table 51. Dong-A ST Major Business

Table 52. Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 53. Dong-A ST Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Metuchen Pharma Corporate Information, Head Office, and Major Competitors

Table 55. Metuchen Pharma Major Business

Table 56. Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 57. Metuchen Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Seoul Pharma Corporate Information, Head Office, and Major Competitors

Table 59. Seoul Pharma Major Business

Table 60. Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 61. Seoul Pharma Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Vectura Group Corporate Information, Head Office, and Major Competitors

Table 63. Vectura Group Major Business

Table 64. Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Product and Solutions

Table 65. Vectura Group Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 66. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 67. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 68. Breakdown of Phosphodiesterase Type 5 (PDE5) Inhibitor by Company Type (Tier 1, Tier 2 and Tier 3)

Table 69. Phosphodiesterase Type 5 (PDE5) Inhibitor Players Head Office, Products and Services Provided

Table 70. Phosphodiesterase Type 5 (PDE5) Inhibitor Mergers & Acquisitions in the Past Five Years

Table 71. Phosphodiesterase Type 5 (PDE5) Inhibitor New Entrants and Expansion Plans

Table 72. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million) by Type (2017-2022)

Table 73. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Share by Type (2017-2022)

Table 74. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Forecast by Type (2023-2028)

Table 75. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2017-2022)

Table 76. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Forecast by Application (2023-2028)

Table 77. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2017-2022) & (USD Million)

Table 78. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2023-2028) & (USD Million)

Table 79. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2017-2022) & (USD Million)

Table 80. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2023-2028) & (USD Million)

Table 81. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Country (2017-2022) & (USD Million)

Table 82. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Country (2023-2028) & (USD Million)

Table 83. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2017-2022) & (USD Million)

Table 84. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2023-2028) & (USD Million)

Table 85. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2017-2022) & (USD Million)

Table 86. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2023-2028) & (USD Million)

Table 87. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Country (2017-2022) & (USD Million)

Table 88. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Country (2023-2028) & (USD Million)

Table 89. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2017-2022) & (USD Million)

Table 90. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2023-2028) & (USD Million)

Table 91. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2017-2022) & (USD Million)

Table 92. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2023-2028) & (USD Million)

Table 93. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Region (2017-2022) & (USD Million)

Table 94. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Region (2023-2028) & (USD Million)

Table 95. South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2017-2022) & (USD Million)

Table 96. South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2023-2028) & (USD Million)

Table 97. South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2017-2022) & (USD Million)

Table 98. South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2023-2028) & (USD Million)

Table 99. South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Country (2017-2022) & (USD Million)

Table 100. South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Country (2023-2028) & (USD Million)

Table 101. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2017-2022) & (USD Million)

Table 102. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Type (2023-2028) & (USD Million)

Table 103. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2017-2022) & (USD Million)

Table 104. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Application (2023-2028) & (USD Million)

Table 105. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Country (2017-2022) & (USD Million)

Table 106. Middle East & Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Phosphodiesterase Type 5 (PDE5) Inhibitor Picture

Figure 2. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Type in 2021

Figure 3. Sildenafil

Figure 4. Tadalafil

Figure 5. Avanafil

Figure 6. Vardenafil

Figure 7. Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Application in 2021

Figure 8. Hospital Picture

Figure 9. Retail Pharmacy Picture

Figure 10. Online Pharmacies Picture

Figure 11. Other Picture

Figure 12. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 13. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Forecast (2017-2028) & (USD Million)

Figure 14. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Region (2017-2028)

Figure 15. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Region in 2021

Figure 16. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million) and Growth Rate (2017-2028)

Figure 17. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Drivers

Figure 22. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Restraints

Figure 23. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Trends

Figure 24. Eli Lilly Recent Developments and Future Plans

Figure 25. Pfizer Recent Developments and Future Plans

Figure 26. Bayer Recent Developments and Future Plans

Figure 27. Novartis AG Recent Developments and Future Plans

Figure 28. Merck Recent Developments and Future Plans

Figure 29. GlaxoSmithKline plc Recent Developments and Future Plans

Figure 30. Roche Recent Developments and Future Plans

Figure 31. AstraZeneca Recent Developments and Future Plans

Figure 32. BaiYunShan General Factory Recent Developments and Future Plans

Figure 33. SK Chemicals Recent Developments and Future Plans

Figure 34. Teva Pharma Recent Developments and Future Plans

Figure 35. Dong-A ST Recent Developments and Future Plans

Figure 36. Metuchen Pharma Recent Developments and Future Plans

Figure 37. Seoul Pharma Recent Developments and Future Plans

Figure 38. Vectura Group Recent Developments and Future Plans

Figure 39. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Share by Players in 2021

Figure 40. Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 41. Global Top 3 Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share in 2021

Figure 42. Global Top 10 Players Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share in 2021

Figure 43. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 44. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Share by Type in 2021

Figure 45. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share Forecast by Type (2023-2028)

Figure 46. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Share by Application in 2021

Figure 47. Global Phosphodiesterase Type 5 (PDE5) Inhibitor Market Share Forecast by Application (2023-2028)

Figure 48. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Market Share by Type (2017-2028)

Figure 49. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Market Share by Application (2017-2028)

Figure 50. North America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Country (2017-2028)

Figure 51. United States Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Canada Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Mexico Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Market Share by Type (2017-2028)

Figure 55. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Market Share by Application (2017-2028)

Figure 56. Europe Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Country (2017-2028)

Figure 57. Germany Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. France Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. United Kingdom Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Russia Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Italy Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Market Share by Type (2017-2028)

Figure 63. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Market Share by Application (2017-2028)

Figure 64. Asia-Pacific Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Region (2017-2028)

Figure 65. China Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. Japan Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. South Korea Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. India Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Southeast Asia Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Australia Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. South America Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Market Share by Type (2017-2028)

Figure 72. South America Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Market Share by Application (2017-2028)

Figure 73. South America Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Country (2017-2028)

Figure 74. Brazil Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Argentina Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Market Share by Type (2017-2028)

Figure 77. Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Sales Market Share by Application (2017-2028)

Figure 78. Middle East and Africa Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue Market Share by Country (2017-2028)

Figure 79. Turkey Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Saudi Arabia Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. UAE Phosphodiesterase Type 5 (PDE5) Inhibitor Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. Methodology

Figure 83. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketsandresearch.biz